Skip to Main Content
Table 2

Association of increased ETAR expression with clinicopathological variables in primary breast cancer patients

Clinicopathological variablesETAR staining n positive/total (%)P                  a
PT stage   
 ≤pT2 53/120 (44.2) NSb; 0.642 
 ≥pT3 21/39 (53.9)  
Lymph node status   
 Negative 35/87 (40.2) NS; 0.137 
 Positive 36/69 (52.2)  
Histologic grading   
 I–II 38/98 (38.8) 0.009 
 III 36/60 (60.0)  
ER status   
 Positive 52/96 (54.2) 0.038 
 Negative 21/57 (36.8)  
PR status   
 Positive 36/73 (49.3) NS; 0.760 
 Negative 37/79 (46.8)  
Her-2/neu status   
 Negative 63/143 (44.0) 0.003 
 Positive 10/11 (90.9)  
MIB-1-labeling index   
 ≤20% 45/99 (45.5) NS; 0.590 
 >20% 27/54 (50.0)  
Lymphovascular invasion   
 No 51/122 (41.8) 0.030 
 Yes 23/37 (62.2)  
Local recurrence   
 No 60/138 (43.5) 0.047 
 Yes 14/21 (66.7)  
Distant metastasis   
 No 46/114 (40.3) 0.013 
 Yes 28/45 (62.2)  
5-yr DFST   
 Yes 36/94 (38.3) 0.030 
 No 24/41 (58.5)  
Clinicopathological variablesETAR staining n positive/total (%)P                  a
PT stage   
 ≤pT2 53/120 (44.2) NSb; 0.642 
 ≥pT3 21/39 (53.9)  
Lymph node status   
 Negative 35/87 (40.2) NS; 0.137 
 Positive 36/69 (52.2)  
Histologic grading   
 I–II 38/98 (38.8) 0.009 
 III 36/60 (60.0)  
ER status   
 Positive 52/96 (54.2) 0.038 
 Negative 21/57 (36.8)  
PR status   
 Positive 36/73 (49.3) NS; 0.760 
 Negative 37/79 (46.8)  
Her-2/neu status   
 Negative 63/143 (44.0) 0.003 
 Positive 10/11 (90.9)  
MIB-1-labeling index   
 ≤20% 45/99 (45.5) NS; 0.590 
 >20% 27/54 (50.0)  
Lymphovascular invasion   
 No 51/122 (41.8) 0.030 
 Yes 23/37 (62.2)  
Local recurrence   
 No 60/138 (43.5) 0.047 
 Yes 14/21 (66.7)  
Distant metastasis   
 No 46/114 (40.3) 0.013 
 Yes 28/45 (62.2)  
5-yr DFST   
 Yes 36/94 (38.3) 0.030 
 No 24/41 (58.5)  
a

χ2 test.

b

NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal